An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib in Participants With Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTL CEBPA (Primary) ; Sorafenib (Primary)
Indications Liver cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OUTREACH2
Sponsors MiNA Therapeutics

Most Recent Events

06 Mar 2025 Status changed from active, no longer recruiting to completed.
24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
04 Jan 2023 This trial has been suspended in Sweden, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight